TD Cowen Maintains Buy on AVITA Medical, Raises Price Target to $14
TD Cowen analyst Joshua Jennings maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $12 to $14.
Read original at benzingaEconomy · News reference
AVITA Medical Announces PermeaDerm-I Study Met Primary Endpoint, Delivering Clinically Comparable Outcomes To Cadaveric Allograft With 70% Cost Reduction
Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001) 96% reduction in preparation time and comparable clinical
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 18, 2026, 11:47 AM
- Checked
- Aug 18, 2026, 11:47 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
BTIG Maintains Buy on AVITA Medical, Raises Price Target to $11
BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $7 to $11.
Read original at benzingaAVITA Medical shares are trading higher after the company announced its PermeaDerm-I study met primary endpoint, delivering clinically comparable outcomes to cadaveric allograft with 70% cost reduction.
Read original at benzinga